novo glp-1 drug Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say Novo's Wegovy Inches Closer to

Studies suggest tirzepatide may help improve cardiometabolic risk factors and reduce the risk of atherosclerotic cardiovascular disease (CVD)

a systematic review and meta-analysis: do the benefits outweigh the risks

Conclusion GLP1 agonists, in particular, semaglutide and tirzepatide are remarkably effective weight loss drugs that have demonstrated a myriad of positive health benefits in obese and overweight patients, including, most notably, improved overall survival

Is IIH a disability

After 12 to 18 months, some patients may even be able to stop the GLP-1 drug and use FIM programming for weight maintenance

[DOI] [PMC free article] [PubMed] [Google Scholar] 163.Li Z, et al